IART Stock Overview
Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, and general surgery.
Integra LifeSciences Holdings Corporation Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$57.07|
|52 Week High||US$76.70|
|52 Week Low||US$51.21|
|1 Month Change||10.64%|
|3 Month Change||-3.79%|
|1 Year Change||-19.65%|
|3 Year Change||-6.47%|
|5 Year Change||13.64%|
|Change since IPO||1,133.95%|
Recent News & Updates
|IART||US Medical Equipment||US Market|
Return vs Industry: IART matched the US Medical Equipment industry which returned -19.1% over the past year.
Return vs Market: IART underperformed the US Market which returned -10.1% over the past year.
|IART Average Weekly Movement||4.4%|
|Medical Equipment Industry Average Movement||9.4%|
|Market Average Movement||7.7%|
|10% most volatile stocks in US Market||16.9%|
|10% least volatile stocks in US Market||3.2%|
Stable Share Price: IART is less volatile than 75% of US stocks over the past 3 months, typically moving +/- 4% a week.
Volatility Over Time: IART's weekly volatility (4%) has been stable over the past year.
About the Company
|1989||3,800||Jan De Witte||https://www.integralife.com|
Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, and general surgery. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as asset management software and support, and after-market services.
Integra LifeSciences Holdings Corporation Fundamentals Summary
|IART fundamental statistics|
Is IART overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|IART income statement (TTM)|
|Cost of Revenue||US$570.60m|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
|Earnings per share (EPS)||1.99|
|Net Profit Margin||10.61%|
How did IART perform over the long term?See historical performance and comparison